Blood
Articles in this Issue
Harnessing neoantigen-specific T cells for precision immunotherapy in hematologic malignancies
Abstract Antigen-specific T-cell immunotherapies are transforming the treatment landscape of hematologic malignancies. Neoantigen-specific therapies that exploit the ability of end...
Balancing risk: anemia or albuminuria when using ACEi/ARB?
Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study
Abstract This prespecified AZALEA-TIMI 71 analysis showed that prior oral anticoagulation (OAC) experience indicates bleeding risk in atrial fibrillation. The factor XI inhibitor a...
Stag2-dependent chromatin remodeling enforces the erythroid-specific Gata1 cistrome
Abstract The transcription factor GATA1 has pleiotropic hematopoietic functions, particularly in erythroid and megakaryocytic ontogeny. Although mechanistic investigations have unc...
Between a clot and a hard place: role of FXIa inhibition
Renin-angiotensin-aldosterone system inhibition exacerbates anemia in sickle cell disease
Abstract Renin-angiotensin-aldosterone system inhibitors (RAASi) are suggested for treating albuminuria in patients with sickle cell disease (SCD). RAASi may exacerbate anemia in t...
Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study
Abstract Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), especially those progressing after Bruton tyrosine kinase (BTK) inhibitor and/or chimeric antigen recep...
Single-day nonactivated IL-18–armed CAR T cells establish a durable, stemlike state with enhanced persistence
Abstract Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of B-cell malignancies, yet challenges including manufacturing delays, T-cell exhaustion, a...
Chromatin’s compass
Boosting HSC functions: <scp>l</scp> -carnitine takes center stage
LCK-targeting molecular glues overcome resistance to inhibitor-based therapy in T-cell acute lymphoblastic leukemia
Abstract Drug resistance is a major challenge in cancer therapy, especially in hematologic malignancies in which kinase inhibitors have transformed treatment yet are frequently und...
T-ALL micro(RNA)management: miR-15b and -16-2 join the team
<scp>l</scp> -Carnitine regulates regeneration of human hematopoietic stem and progenitor cells
Abstract Understanding how metabolism governs human hematopoietic stem cells (HSCs) function is essential for advancing regenerative therapies, yet direct metabolic profiling of hu...
Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma, <i>Blood</i> . 2008;111(4):2230-2237.
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models
Abstract The protein-protein interaction between menin and KMT2A (histone lysine methyltransferase 2A) plays a critical role in acute leukemia with KMT2A rearrangements, nucleophos...
Two birds with one stone: faster, fitter CAR T cells
How soon is now for new treatments for mantle cell lymphoma?
Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study
Abstract The use of chimeric antigen receptor (CAR) T-cell therapy is increasing for adult B-cell acute lymphoblastic leukemia (B-ALL), with 3 CD19 CAR T-cell products commercially...
Disseminated cryptococcal lymphadenitis mimicking lymphoma and masked by prozone effect
A tumor suppressor role of the miR-15b/16-2 cluster in T-cell acute lymphoblastic leukemia
Abstract T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy arising from the neoplastic transformation of immature T cells during their developme...